It doesn't apply to emergencies.
Read More
It hasn’t undergone phase 3 clinical trials.
This will affect Arctic communities.
The effects of other viruses that cause colds stimulate an immune system response in a percentage of the population that would range from a minimum of 20% to 80%
The Russian prototype, one of the 167 registered by the WHO, has not yet demonstrated its effectiveness and safety in tests with tens of thousands of people